XML 24 R46.htm IDEA: XBRL DOCUMENT
v2.4.1.9

Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail) (USD $) In Thousands, unless otherwise specified | 3 Months Ended | 12 Months Ended
--- | --- | ---
Sep. 30, 2014 | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012
Biogen [Member] |  |  |  |
Revenue related to Biogen Collaboration: |  |  |  |
Recognition of upfront fee |  | $ 5,313 us-gaap_LicenseAndServicesRevenue / us-gaap_CounterpartyNameAxis = sgmo_BiogenMember |  |
Research services |  | 7,751 sgmo_ResearchServiceRevenueUnderCollaborationAgreement / us-gaap_CounterpartyNameAxis = sgmo_BiogenMember |  |
Total |  | 13,064 us-gaap_ContractsRevenue / us-gaap_CounterpartyNameAxis = sgmo_BiogenMember |  |
Shire AG [Member] |  |  |  |
Revenue related to Biogen Collaboration: |  |  |  |
Recognition of milestone | 1,000 us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized / us-gaap_CounterpartyNameAxis = sgmo_ShireAgMember | 1,000 us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized / us-gaap_CounterpartyNameAxis = sgmo_ShireAgMember |  |
Royalty revenues |  | 0 us-gaap_RoyaltyRevenue / us-gaap_CounterpartyNameAxis = sgmo_ShireAgMember |  |
Research services |  | 22,765 sgmo_ResearchServiceRevenueUnderCollaborationAgreement / us-gaap_CounterpartyNameAxis = sgmo_ShireAgMember | 14,286 sgmo_ResearchServiceRevenueUnderCollaborationAgreement / us-gaap_CounterpartyNameAxis = sgmo_ShireAgMember | 9,026 sgmo_ResearchServiceRevenueUnderCollaborationAgreement / us-gaap_CounterpartyNameAxis = sgmo_ShireAgMember
Total |  | 25,932 us-gaap_ContractsRevenue / us-gaap_CounterpartyNameAxis = sgmo_ShireAgMember | 16,453 us-gaap_ContractsRevenue / us-gaap_CounterpartyNameAxis = sgmo_ShireAgMember | 11,012 us-gaap_ContractsRevenue / us-gaap_CounterpartyNameAxis = sgmo_ShireAgMember
Shire AG [Member] | Upfront Fee And Milestone Revenue |  |  |  |
Revenue related to Biogen Collaboration: |  |  |  |
Recognition of upfront fee |  | 2,167 us-gaap_LicenseAndServicesRevenue / us-gaap_CounterpartyNameAxis = sgmo_ShireAgMember / us-gaap_DeferredRevenueArrangementTypeAxis = sgmo_UpfrontFeeAndMilestoneRevenueMember | 2,167 us-gaap_LicenseAndServicesRevenue / us-gaap_CounterpartyNameAxis = sgmo_ShireAgMember / us-gaap_DeferredRevenueArrangementTypeAxis = sgmo_UpfrontFeeAndMilestoneRevenueMember | 1,986 us-gaap_LicenseAndServicesRevenue / us-gaap_CounterpartyNameAxis = sgmo_ShireAgMember / us-gaap_DeferredRevenueArrangementTypeAxis = sgmo_UpfrontFeeAndMilestoneRevenueMember
Sigma-Aldrich Corporation [Member] |  |  |  |
Revenue related to Biogen Collaboration: |  |  |  |
Royalty revenues |  | 344 us-gaap_RoyaltyRevenue / us-gaap_CounterpartyNameAxis = sgmo_SigmaAldrichCorporationMember | 824 us-gaap_RoyaltyRevenue / us-gaap_CounterpartyNameAxis = sgmo_SigmaAldrichCorporationMember | 1,288 us-gaap_RoyaltyRevenue / us-gaap_CounterpartyNameAxis = sgmo_SigmaAldrichCorporationMember
License fee and milestone revenues |  | 448 us-gaap_LicensesRevenue / us-gaap_CounterpartyNameAxis = sgmo_SigmaAldrichCorporationMember | 1,351 us-gaap_LicensesRevenue / us-gaap_CounterpartyNameAxis = sgmo_SigmaAldrichCorporationMember | 1,000 us-gaap_LicensesRevenue / us-gaap_CounterpartyNameAxis = sgmo_SigmaAldrichCorporationMember
Total |  | $ 792 us-gaap_ContractsRevenue / us-gaap_CounterpartyNameAxis = sgmo_SigmaAldrichCorporationMember | $ 2,175 us-gaap_ContractsRevenue / us-gaap_CounterpartyNameAxis = sgmo_SigmaAldrichCorporationMember | $ 2,288 us-gaap_ContractsRevenue / us-gaap_CounterpartyNameAxis = sgmo_SigmaAldrichCorporationMember

X
- Definition Research service revenue under collaboration agreement. + References No definition available. + Details
Name: | sgmo_ResearchServiceRevenueUnderCollaborationAgreement
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, construction contracts, and any other contract related to a particular project or product. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_ContractsRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(d),(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_LicenseAndServicesRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_LicensesRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_RevenuesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details
Name: | us-gaap_RoyaltyRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_CounterpartyNameAxis=sgmo_BiogenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |